Harmony Biosciences Q4 2023 Adj EPS $0.73 Beats $0.48 Estimate, Sales $168.41M Miss $169.06M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences (NASDAQ:HRMY) reported Q4 2023 adjusted EPS of $0.73, surpassing the $0.48 estimate, marking a 52.08% beat but a 27.72% decrease from last year's $1.01. Sales reached $168.41M, slightly missing the $169.06M estimate by 0.38%, yet showing a 31.26% increase from the previous year.
February 22, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harmony Biosciences reported a strong Q4 2023 EPS beat but a slight miss on sales estimates. The EPS of $0.73 exceeded expectations by 52.08%, despite being lower than last year's $1.01. Sales grew 31.26% YOY to $168.41M, missing estimates by a narrow margin.
The significant beat on the EPS estimate is likely to be viewed positively by investors, indicating strong profitability. However, the slight miss on sales and the decrease in EPS from the previous year might temper some of the enthusiasm. Overall, the strong EPS beat combined with continued sales growth suggests a positive short-term impact on HRMY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100